![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/05/2893738/0/en/ACELYRIN-INC-Announces-Positive-16-week-Data-From-its-Global-Phase-2b-3-Trial-of-Izokibep-in-Psoriatic-Arthritis-to-be-Shared-During-Late-Breaking-Oral-Presentation-at-EULAR-2024.html
https://www.globenewswire.com/news-release/2024/05/29/2889711/0/en/ACELYRIN-INC-Announces-Lonigutamab-Phase-1-2-Proof-Of-Concept-Data-to-be-Shared-During-Late-Breaking-Oral-Presentation-at-ENDO-2024.html
https://www.biospace.com/article/releases/acelyrin-inc-announces-leadership-transition-may-09-2024/
https://www.globenewswire.com/news-release/2024/05/09/2878734/0/en/ACELYRIN-INC-Provides-Business-Update-and-Highlights-Key-Upcoming-Milestones.html
https://www.globenewswire.com/news-release/2024/05/09/2878720/0/en/ACELYRIN-INC-Announces-Leadership-Transition.html
https://www.globenewswire.com/news-release/2024/04/29/2871632/0/en/ACELYRIN-INC-to-Report-First-Quarter-2024-Financial-Results-and-Corporate-Update-on-May-13-2024.html
https://www.globenewswire.com/news-release/2024/03/28/2854476/0/en/ACELYRIN-INC-Reports-Full-Year-2023-Financial-Results-and-Recent-Highlights.html
https://www.globenewswire.com/news-release/2024/03/20/2849228/0/en/ACELYRIN-INC-Announces-Positive-Phase-1-2-Proof-of-Concept-Data-for-Lonigutamab-First-Subcutaneous-Anti-IGF-1R-to-Demonstrate-Clinical-Responses-in-Thyroid-Eye-Disease.html
https://www.fiercebiotech.com/biotech/acelyrin-adds-proof-concept-ted-data-recent-readout-pile-cementing-direct-challenge-amgen
https://www.fiercebiotech.com/biotech/acelyrin-rebounds-psoriatic-arthritis-victory